Koselugo(Selumetinib) Side Effects

KOSELUGO is associated with a high incidence of gastrointestinal, dermatologic, and musculoskeletal adverse reactions.

Adverse Reaction Profile of KOSELUGO


The most common side effects of KOSELUGO include vomiting, rash, abdominal pain, diarrhea, nausea, dry skin, fatigue, musculoskeletal pain, fever, acneiform rash, stomatitis, headache, paronychia, and pruritus, with many occurring in over 40% of patients. Serious adverse events such as cardiomyopathy, ocular toxicity, increased creatine phosphokinase, and risk of bleeding have also been reported. Laboratory abnormalities include elevated creatine phosphokinase, liver enzymes, and decreased blood counts. Permanent discontinuation due to adverse reactions occurred in 12% of patients. Long-term safety data and effects in populations outside the studied group are not specified in the description.

Selumetinib(Koselugo)
KOSELUGO (selumetinib) is indicated for the treatment of pediatric patients aged 2 years and older who have been diagnosed with neurofibromatosis type 1 (NF1) and present with...
RELATED ARTICLES
Adverse reactions caused by Selumetinib bisulfate capsules

The U.S. FDA Approved Selumetinib (Koselugo) for the Treatment of Pediatric Patients 2 years of age and older with...

Tuesday, June 24th, 2025, 17:12
Selumetinib side effects

Selumetinib is a targeted drug for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform...

Tuesday, June 24th, 2025, 17:00
Adverse effects of Selumetinib

As a highly effective tyrosine kinase inhibitor, Selumetinib has shown significant anti-lesion effect in...

Tuesday, June 24th, 2025, 16:56
/ 1
3 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved